Literature DB >> 23815443

Targeted delivery of Epirubicin to cancer cells by PEGylated A10 aptamer.

Seyed Mohammad Taghdisi1, Noor Mohammad Danesh, Ahmad Sarreshtehdar Emrani, Kaveh Tabrizian, Majid Zandkarimi, Mohammad Ramezani, Khalil Abnous.   

Abstract

Clinical administrations of anthracyclines are limited by cardiotoxicity and myelosuppression. Targeted delivery of anticancer agents is especially important in reducing their side effects. In this work, A10 (Apt), an aptamer for prostate-specific membrane anytigen (PSMA), was applied for targeted delivery of Epirubicin (Epi) to LNCaP cells (PSMA(+)). Flow cytometry analysis showed that PEG-Apt-Epi complex was internalized effectively to LNCaP cells (PSMA(+)), but not to PC3 cells (PSMA(-)). This fact was confirmed by less cytotoxicity of PEG-Apt-Epi complex in PC3 cells in comparison with Epi alone. No significant change in viability between Epi- and complex-treated LNCaP cells was observed. In conclusion, PEG-Apt-Epi complex is an efficient and simple system for specific delivery of drug to PSMA-expressing cell lines.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23815443     DOI: 10.3109/1061186X.2013.812095

Source DB:  PubMed          Journal:  J Drug Target        ISSN: 1026-7158            Impact factor:   5.121


  13 in total

1.  Targeted Delivery of Epirubicin to Cancer Cells by Polyvalent Aptamer System in vitro and in vivo.

Authors:  Rezvan Yazdian-Robati; Mohammad Ramezani; Seyed Hamid Jalalian; Khalil Abnous; Seyed Mohammad Taghdisi
Journal:  Pharm Res       Date:  2016-06-09       Impact factor: 4.200

Review 2.  Aptamer-Functionalized Nanoparticles as "Smart Bombs": The Unrealized Potential for Personalized Medicine and Targeted Cancer Treatment.

Authors:  Gregory Benedetto; C Greer Vestal; Christine Richardson
Journal:  Target Oncol       Date:  2015-12       Impact factor: 4.493

Review 3.  Aptamers and their applications in nanomedicine.

Authors:  Hongguang Sun; Youli Zu
Journal:  Small       Date:  2015-02-11       Impact factor: 13.281

Review 4.  The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease.

Authors:  James C Evans; Meenakshi Malhotra; John F Cryan; Caitriona M O'Driscoll
Journal:  Br J Pharmacol       Date:  2016-09-23       Impact factor: 8.739

5.  Application of aptamers in diagnostics, drug-delivery and imaging.

Authors:  Chetan Chandola; Sheetal Kalme; Marco G Casteleijn; Arto Urtti; Muniasamy Neerathilingam
Journal:  J Biosci       Date:  2016-09       Impact factor: 2.795

6.  Study on the prostate cancer-targeting mechanism of aptamer-modified nanoparticles and their potential anticancer effect in vivo.

Authors:  Xin Wu; Zongguang Tai; Quangang Zhu; Wei Fan; Baoyue Ding; Wei Zhang; Lijuan Zhang; Chong Yao; Xiaoyu Wang; Xueying Ding; Qin Li; Xiaoyu Li; Gaolin Liu; Jiyong Liu; Shen Gao
Journal:  Int J Nanomedicine       Date:  2014-11-21

Review 7.  Development of Cell-SELEX Technology and Its Application in Cancer Diagnosis and Therapy.

Authors:  Man Chen; Yuanyuan Yu; Feng Jiang; Junwei Zhou; Yongshu Li; Chao Liang; Lei Dang; Aiping Lu; Ge Zhang
Journal:  Int J Mol Sci       Date:  2016-12-10       Impact factor: 5.923

8.  Evaluation of Outcome and Tolerability of Combination Chemotherapy with Capecitabine and Oxaliplatin as First Line Therapy in Advanced Gastric Cancer.

Authors:  Mohammad Ali Mashhadi; Zahra Sepehri; Ali Reza Bakhshipour; Ali Zivari; Hossein Ali Danesh; Hasan Ali Metanat; Azra Karimkoshteh; Seyed Mehdi Hashemi; Hossein Rahimi; Zohre Kiani
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2016-10-01

Review 9.  Selection of Nucleic Acid Aptamers Targeting Tumor Cell-Surface Protein Biomarkers.

Authors:  Marie-Cécile Mercier; Monique Dontenwill; Laurence Choulier
Journal:  Cancers (Basel)       Date:  2017-06-21       Impact factor: 6.639

10.  Oligonucleotide aptamers: new tools for targeted cancer therapy.

Authors:  Hongguang Sun; Xun Zhu; Patrick Y Lu; Roberto R Rosato; Wen Tan; Youli Zu
Journal:  Mol Ther Nucleic Acids       Date:  2014-08-05       Impact factor: 10.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.